Equities

CARsgen Therapeutics Holdings Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

CARsgen Therapeutics Holdings Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)14.40
  • Today's Change0.40 / 2.86%
  • Shares traded747.50k
  • 1 Year change+50.79%
  • Beta1.2946
Data delayed at least 15 minutes, as of Feb 13 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

CARsgen Therapeutics Holdings Ltd is an investment holding company primarily engaged in discovering, researching and developing cell therapies. The Company’s main business is engaged in developing chimeric antigen receptor T cell (CAR T) -cell therapies to address clinical needs including but not limited to hematologic malignancies solid tumors and autoimmune diseases. The Company’s main products include zevor-cel (zevorcabtagene autoleucel), satricabtagene autoleucel and allogeneic CAR T-cell products. The Company conducts its business in the domestic and overseas markets.

  • Revenue in HKD (TTM)95.19m
  • Net income in HKD-591.11m
  • Incorporated2018
  • Employees371.00
  • Location
    CARsgen Therapeutics Holdings Ltd1F, Building 2,No. 466 Yindu Road, XuhuSHANGHAI ChinaCHN
  • Websitehttps://www.carsgen.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Qyuns Therapeutics Co Ltd362.84m-217.22m4.64bn337.00--17.88--12.77-0.978-0.9781.631.150.29034.059.141,070,314.00-17.90---28.45--72.44---61.64--1.43-23.190.7466------33.91------
Jacobio Pharmaceuticals Group Co Ltd228.07m-51.70m4.72bn211.00--4.82--20.70-0.0668-0.06680.29481.250.1547--7.97887,438.90-3.51-36.09-4.01-39.58100.0065.67-22.67-283.16----0.1415--145.13--56.64--29.33--
TYK Medicines Inc121.19k-317.21m4.86bn163.00--11.74--40,143.25-0.8554-0.85540.00031.090.0002----792.07-42.68------13.08---263,981.30------0.3215-------1.18------
Laekna Inc0.00-272.08m5.56bn84.00--6.29-----0.7398-0.73980.001.980.00----0.00-27.79---34.25--------------0.1383------31.05------
Edding Genor Group Holdings Ltd253.70m22.82m6.09bn17.0067.631.28175.0824.000.04500.04500.48852.370.1724--5.2110,571,020.001.46-48.631.72-55.1999.5697.888.45-2,303.07----0.0007----73.7192.40---43.79--
MiRXES Holding Co Ltd-100.00bn-100.00bn6.59bn347.00--7.40----------2.99------------------------3.83--0.1682---16.14---33.37------
CARsgen Therapeutics Holdings Ltd95.19m-591.11m8.21bn371.00--7.61--86.28-1.08-1.080.1731.890.04655.137.63203,396.60-28.88-76.51-32.44-89.2550.57---621.16-12,640.866.40--0.0672-------6.73---28.32--
Lepu Biopharma Co Ltd793.33m-200.70m8.37bn546.00--9.40--10.55-0.1173-0.11730.46370.49340.29172.3518.331,593,024.00-8.24-24.70-14.39-37.7188.41---28.26-459.370.5915-5.030.5632--63.21---1,761.77---29.86--
Abbisko Cayman Ltd700.89m169.87m8.64bn226.0049.283.4443.5912.330.26080.26081.113.740.2634--155.742,494,268.006.38-37.376.83-39.08100.00--24.24-625.86----0.0542--2,544.24--106.56--16.58--
Alphamab Oncology890.17m263.68m8.69bn484.0034.144.1025.229.760.26270.26270.89452.190.34920.825423.762,119,453.0010.35-9.9612.30-11.7592.27--29.62-103.284.75--0.1285--192.58--178.99---33.81--
GenFleet Therapeutics (Shanghai) Inc219.10m-1.05bn11.19bn94.00------51.08-3.04-3.040.6344-8.66----------------80.86---479.17--0.1655-23.43----42.00---33.31------
Suzhou Ribo Life Science Co Ltd204.02m-250.00m11.95bn404.00------58.56-1.55-1.551.26-0.4093----------------90.90---131.95--0.9173-14.930.8949--324,052.30--36.93------
Nanjing Leads Biolabs Co Ltd0.00-325.29m12.20bn192.00--97.39-----2.01-2.010.000.6299------------------------1.01--0.7407---100.00--16.85------
Data as of Feb 13 2026. Currency figures normalised to CARsgen Therapeutics Holdings Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

4.43%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 07 Jan 202614.15m2.45%
Norges Bank Investment Managementas of 30 Jun 20256.22m1.08%
BlackRock Advisors (UK) Ltd.as of 09 Jan 20261.18m0.20%
JPMorgan Asset Management (UK) Ltd.as of 30 Jun 20251.05m0.18%
SSgA Funds Management, Inc.as of 08 Jan 2026941.50k0.16%
Goldman Sachs Asset Management LPas of 31 Oct 2025645.50k0.11%
Vanguard Fiduciary Trust Co.as of 30 Nov 2025408.50k0.07%
BlackRock Fund Advisorsas of 08 Jan 2026346.00k0.06%
Bellecapital AGas of 30 Jun 2025320.00k0.06%
TIAA-CREF Investment Management LLCas of 31 Dec 2025310.50k0.05%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.